yes the problem isn’t the science, it’s the whole Paul hopper portfolio, it doesn’t take much to work out he sells out his own companies to Soph’s and burns retail along the way, two of his companies down over 90% in two years while its peers are thriving
compare rad to cu6 for example
the constan CR’s, discounts and dilution has decimated the SP
Ann: 1st patient treated in ADVENT-AML Phase 1b clinical trial, page-69
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
-0.002(13.0%) |
Mkt cap ! $9.951M | |||
| Open | High | Low | Value | Volume |
| 1.1¢ | 1.1¢ | 1.0¢ | $13.65K | 1.300M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 2625597 | 1.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.1¢ | 88904 | 3 |
View Market Depth
| Last trade - 16.10pm 07/11/2024 (20 minute delay) ? |
| CHM (ASX) Chart |